Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation

纳米载体 药代动力学 顺铂 乳腺癌 药理学 化学 三阴性乳腺癌 癌症 医学 癌症研究 肿瘤科 内科学 药品 化疗
作者
Terrick A. Andey,Sudhakar Godeshala,Srujan Kumar Marepally,Apurva R. Patel,Rintu Banerjee‬‬‬‬‬‬‬‬‬,Mandip S. Singh
出处
期刊:Molecular Pharmaceutics [American Chemical Society]
卷期号:12 (4): 1105-1120 被引量:77
标识
DOI:10.1021/mp5008629
摘要

Breast cancer is the leading cause of malignancies among women globally. The triple negative breast cancer (TNBC) subtype is the most difficult to treat and accounts for 15% of all cases. Targeted therapies have been developed for TNBC but come short of clinical translation due to acquired tumor resistance. An effective therapy against TNBC must combine properties of target specificity, efficient tumor killing, and translational relevance. The objective of this study was to formulate a nontoxic, cationic, lipid-conjugated estrogenic derivative (ESC8), with demonstrated anticancer activity, for oral delivery in mice bearing triple negative breast cancer (TNBC) as xenograft tumors. The in vitro cell viability, Caco-2 permeability, and cell cycle dynamics of ESC8-treated TNBC cells were investigated. ESC8 was formulated as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) and characterized for size, zeta potential, entrapment efficiency, size stability, and tumor biodistribution. Pharmacokinetic modeling of plasma concentration-time course data was carried out following intravenous and oral administration in Sprague-Dawley rats. In vivo efficacy investigation of ESC8-SLNC was carried out in Nu/Nu mice bearing MDA-MB-231 TNBC as xenograft tumors, and the molecular dynamics modulating tumor growth inhibition was analyzed by Western blot. In vitro ESC8 inhibited TNBC and non-TNBC cell viability with IC50 ranging from 1.81 to 3.33 μM. ESC8 was superior to tamoxifen and Cisplatin in inhibiting MDA-MB-231 cell viability; and at 2.0 μM ESC8 enhanced Cisplatin cytotoxicity 16-fold. Intravenous ESC8 (2.0 mg/kg) was eliminated at a rate of 0.048 ± 0.01 h(-1) with a half-life of 14.63 ± 2.95 h in rats. ESC8 was orally bioavailable (47.03%) as solid lipid nanoparticles (ESC8-SLN). ESC8-SLN (10 mg/kg/day, ×14 days, p.o.) inhibited breast tumor growth by 74% (P < 0.0001 vs control) in mice bearing MDA-MB-231 cells as xenografts; and when given in combination with Cisplatin (2.0 mg/kg/biweekly, ×2 weeks, IV), tumor growth was inhibited by 87% (P = 0.0002, vs ESC8-SLN; 10 mg/kg/day, ×14 days, p.o). ESC8-SLN tumor growth inhibition was associated with increased expression of p21 and Caspase-9; as well as by inhibition of EGFR, Slug, p-Akt1, Vimentin, NFkβ, and IKKγ. These results show the promise of ESC8 as an oral adjuvant or neoadjuvant against triple negative breast cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zzxiao完成签到,获得积分10
刚刚
1秒前
1秒前
meng发布了新的文献求助10
1秒前
年轻怀绿完成签到,获得积分10
1秒前
benihikari给benihikari的求助进行了留言
2秒前
上帝的笑完成签到,获得积分10
2秒前
椒盐丸子完成签到,获得积分10
2秒前
2秒前
2秒前
guo完成签到 ,获得积分10
2秒前
鳗鱼雪巧完成签到,获得积分10
3秒前
3秒前
好家伙发布了新的文献求助10
3秒前
爆米花的应助被董家旭采纳,获得10
3秒前
悄悄Margaret完成签到,获得积分10
3秒前
kinlo97完成签到,获得积分10
3秒前
碎觉觉发布了新的文献求助10
3秒前
纯真的志泽完成签到 ,获得积分10
4秒前
ygklda完成签到 ,获得积分10
4秒前
小慕完成签到,获得积分10
4秒前
隐形挑战者完成签到,获得积分10
4秒前
杜小鱼发布了新的文献求助10
4秒前
能干的孤丝完成签到,获得积分10
4秒前
5秒前
贪玩大侠完成签到,获得积分10
5秒前
鲜衣怒马完成签到,获得积分20
5秒前
Hello的应助被未了采纳,获得10
6秒前
不加糖完成签到,获得积分10
6秒前
科研通AI6.3的应助被博修采纳,获得10
6秒前
6秒前
7秒前
7秒前
jia完成签到,获得积分10
7秒前
重要莹发布了新的文献求助10
7秒前
Ceaser完成签到,获得积分10
7秒前
专业海域完成签到,获得积分10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253